Merck and Ono Sign Collaborations for Multiple Sclerosis and Cancer

Merck KGaA has announced that they have signed two agreements for collaboration of their Merck Serono division with Ono Pharmaceutical Co. Ltd., headquartered in Osaka, Japan, to strengthen their multiple sclerosis and cancer franchises. The initial agreement grants Merck Serono exclusive license rights for the development and commercialization of ONO-4641 outside of Japan, Korea and

Continue Reading